Krebs Biochemicals & Industries Share Price
55.00+0.50 (+0.92%)
-24.67% past 1 Year
Krebs Biochemicals & Industries Limited (KBIL) is an India-based company. The Company operates in the pharma segment. The Company’s products include lavastatin, simvastatin and simvastatin ammonium salt. The Company specializes
Corporate filings & documents
Announcements
The Company has enclosed herewith copy of newspaper advertiesment w.r.t. prior intimation of 34th AGM of the Company.
23 hours agoThe Company has enclosed herewith copy of newspaper advertiesment w.r.t. prior intimation of 34th AGM of the Company.
23 hours agoThe Company has enclosed herewith copy of newpapers advertiesment of unaudited financial results for the quarter ended 30.06.2026
4 weeks agoThe Company has enclosed herewith copy of newpapers advertiesment of unaudited financial results for the quarter ended 30.06.2026
4 weeks agoResults for the quarter ended 30602026
4 weeks agoResults for the quarter ended 30602026
4 weeks agoOutcome of BM
4 weeks agoOutcome of BM
4 weeks agoKrebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve Intimation of Board Meeting to be held on 6th Agust 2026 interalia to consider and approve unaudited financial results for the quarter ended 30th June 2026.
1 month agoKrebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve Intimation of Board Meeting to be held on 6th Agust 2026 interalia to consider and approve unaudited financial results for the quarter ended 30th June 2026.
1 month agoThe Company has enclosing herewith Certficate recived from RTA under Reg 74 (5) of DP Regulations 2018 for the quarter ended 31.06.2026.
2 months agoThe Company has enclosing herewith Certficate recived from RTA under Reg 74 (5) of DP Regulations 2018 for the quarter ended 31.06.2026.
2 months agooutcome of Baorad meeting
2 months agooutcome of Baorad meeting
2 months agoOutcome of Board Meeting
2 months agoOutcome of Board Meeting
2 months agoThe Company has enclosed herewith intimation for closure of trading window for the quareter ended 30.06.2026
2 months agoThe Company has enclosed herewith intimation for closure of trading window for the quareter ended 30.06.2026
2 months agoThe Company has enclosed herewith Annual Secretarial Complince Report for the yaer ended 31.03.2026.
3 months agoThe Company has enclosing herewith copy of newspapers advetiement of financial resulst for the quarter and yaer ended 31.03.2026.
3 months agoAudited Results for fiancial yaer ended 31.03.2026
3 months agoOutcome of Board Meeting 21.05.2026
3 months agoOutcome of Board Meeting 21.05.2026
3 months agoKrebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that meeting of the Board of Directors of the Company will be held on Thursday May 21 2026 inter-alia to consider and adopt the audited financial results for the 4th quarter and financial year ended March 31 2026.
3 months agoClarification on price movement
4 months agoClarification on price movement
4 months agoThe Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoThe Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoThe Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations 2018 for the quarter ended 31.03.2026.
5 months agoThe Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations 2018 for the quarter ended 31.03.2026.
5 months agoThe Company has enclosinh herewith intimation for closure of trading window for considaration of audited financial results for the 4th quarter and year ended 31.03.2026.
5 months agoThe Company has enclosing copy of newspaper advertisement of financial results for the quarter ended 31.12.2025
6 months agoResult for the quarter ended 31.12.2025
6 months agoOutcome of Board Meeting
6 months agoKrebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve Board Meeting intimation to consider and adopt the unaudited financial results for the 3rd quarter and nine months ended December 31 2025
7 months agoThe Company has enclosed herewith report on relodgement of shares for the month of December 2025.
8 months agoThe Company has enclosing herewith certificate recived from RTA under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31.12.2025.
8 months agoThe Company has enclosed herewith intimation for closing of trading window for the quarter ended 31.12.2025
8 months agoThe Company enclosing herewith RTA report on relodgement of trasnfer request of physical shares for the month Nov 2025.
9 months agoThe Company has enclosed herewith re-lodgement certificate received from RTA.
9 months agoThe Company has enclosed herewith copy of newspapers advertisement for financial results for the quarter and half year ended 30.09.2025
10 months agoResult Sept 2025
10 months agoOutcome
10 months agoKrebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2025 inter alia to consider and approve The Company has enclosed herewith Board Meting Intimation for quarter ended 30.09.2025.
10 months agoThe Company has received Certificate for Re lodgment of physical shares for the month of Sept 2025.
11 months agoThe Company has enclosed herewith certificate received from RTA for the quarter ended 30.09.2025.
11 months agoThe Company has enclosing herewith voting result and scrutinizer report for 33 rd AGM
11 months agoThe Company has enclosed herewith proceedings of 33rd Annual General Meeting of the Company.
11 months agoThe Company has enclosed herewith intimation of closure of trading window for quarter and half year ended 30.09.2025
11 months agoThe Company has enclosed herewith RTA Report on re-lodgement of transfer requests of physical shares for the period up to 31.08.2025.
11 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2019-01-31
Rights
21:100;86.0 (Rights ratio;Offer price)
Company details
Registered office
Kothapalli Village Anakapalli Kasimkota Mandal Vishakhapatnam Andhra Pradesh PIN: 531031 Tel No: 040-66808040 / 9121144984 Fax No: NULL Email: [email protected] / [email protected] Internet: www.krebsbiochem.com
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Rakesh Kalbate, Company Secretary & Compliance Officer
R T Ravi, Chairman
Manish Jain, Managing Director & CEO
Pabitra Bhattacharya, Non Independent & Non Executive Director
Avinash Ravi, Non Independent & Non Executive Director
PM Kathariya, Non Executive Independent Director
Dipti Shah, Non Executive Independent Director
Satya Prakash Chigurupati, Non Executive Independent Director
Sumanth Karlapudi, Non Executive Independent Director
Details
BSE 524518
NSE KREBSBIO
ISIN INE268B01013